BIIB – Biogen Inc.
Float Short %
4.5
Margin Of Safety %
13
Put/Call OI Ratio
0.71
EPS Next Q Diff
-1.27
EPS Last/This Y
3.82
EPS This/Next Y
0.18
Price
186.96
Target Price
184.56
Analyst Recom
2.28
Performance Q
22.8
Relative Volume
1.1
Beta
0.16
Ticker: BIIB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-09 | BIIB | 175.79 | 0.62 | 0.37 | 74863 |
| 2025-12-10 | BIIB | 177.48 | 0.62 | 1.10 | 75704 |
| 2025-12-11 | BIIB | 173.64 | 0.66 | 1.11 | 79844 |
| 2025-12-12 | BIIB | 174.08 | 0.67 | 0.67 | 80519 |
| 2025-12-15 | BIIB | 175.78 | 0.66 | 0.52 | 79579 |
| 2025-12-16 | BIIB | 171.4 | 0.66 | 0.67 | 79900 |
| 2025-12-17 | BIIB | 172.1 | 0.67 | 0.23 | 80542 |
| 2025-12-18 | BIIB | 169.92 | 0.66 | 0.32 | 81612 |
| 2025-12-19 | BIIB | 174.65 | 0.67 | 0.66 | 82093 |
| 2025-12-22 | BIIB | 174.76 | 0.73 | 0.44 | 67731 |
| 2025-12-23 | BIIB | 174.84 | 0.73 | 0.52 | 68478 |
| 2025-12-26 | BIIB | 176.56 | 0.73 | 0.16 | 68964 |
| 2025-12-29 | BIIB | 176.83 | 0.72 | 1.14 | 67857 |
| 2025-12-30 | BIIB | 176.92 | 0.72 | 0.30 | 68085 |
| 2025-12-31 | BIIB | 176.01 | 0.72 | 0.24 | 68187 |
| 2026-01-02 | BIIB | 177.81 | 0.71 | 0.29 | 68409 |
| 2026-01-05 | BIIB | 174.61 | 0.70 | 0.27 | 68133 |
| 2026-01-06 | BIIB | 182.61 | 0.69 | 0.17 | 71915 |
| 2026-01-07 | BIIB | 186.96 | 0.71 | 0.19 | 71922 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-09 | BIIB | 175.84 | -49.2 | 207.2 | 15.06 |
| 2025-12-10 | BIIB | 175.84 | -49.2 | 284.4 | 15.06 |
| 2025-12-11 | BIIB | 172.50 | -49.2 | 200.7 | 15.06 |
| 2025-12-12 | BIIB | 174.09 | -49.2 | 283.8 | 15.07 |
| 2025-12-15 | BIIB | 175.74 | -49.2 | 284.3 | 15.07 |
| 2025-12-16 | BIIB | 175.74 | -49.0 | 209.0 | 15.07 |
| 2025-12-17 | BIIB | 172.05 | -49.0 | 270.6 | 15.07 |
| 2025-12-18 | BIIB | 169.89 | -49.0 | 235.3 | 15.07 |
| 2025-12-19 | BIIB | 174.67 | -49.0 | 325.1 | 15.07 |
| 2025-12-22 | BIIB | 175.01 | -48.7 | 266.1 | 15.07 |
| 2025-12-23 | BIIB | 174.90 | -48.7 | 261.0 | 15.07 |
| 2025-12-26 | BIIB | 177.08 | -49.2 | 273.0 | 15.03 |
| 2025-12-29 | BIIB | 176.83 | -49.2 | 260.5 | 15.03 |
| 2025-12-30 | BIIB | 176.37 | -49.2 | 257.8 | 15.03 |
| 2025-12-31 | BIIB | 176.05 | -49.2 | 259.2 | 15.03 |
| 2026-01-02 | BIIB | 177.79 | -49.2 | 286.1 | 15.03 |
| 2026-01-05 | BIIB | 174.53 | -49.2 | 222.7 | 15.03 |
| 2026-01-06 | BIIB | 182.50 | -49.2 | 362.8 | 15.03 |
| 2026-01-07 | BIIB | 186.96 | -49.2 | 316.2 | 15.03 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-09 | BIIB | -1.03 | 2.36 | 4.19 |
| 2025-12-10 | BIIB | -1.03 | 2.36 | 4.63 |
| 2025-12-11 | BIIB | -1.03 | 2.36 | 4.63 |
| 2025-12-12 | BIIB | -1.03 | 2.36 | 4.63 |
| 2025-12-15 | BIIB | -1.03 | 2.35 | 4.63 |
| 2025-12-16 | BIIB | -1.03 | 2.35 | 4.63 |
| 2025-12-17 | BIIB | -1.03 | 2.35 | 4.63 |
| 2025-12-18 | BIIB | -1.03 | 2.35 | 4.63 |
| 2025-12-19 | BIIB | -1.03 | 2.35 | 4.63 |
| 2025-12-22 | BIIB | -1.03 | 2.34 | 4.63 |
| 2025-12-23 | BIIB | -1.03 | 2.34 | 4.63 |
| 2025-12-26 | BIIB | -1.03 | 2.34 | 4.50 |
| 2025-12-29 | BIIB | -1.03 | 2.35 | 4.50 |
| 2025-12-30 | BIIB | -1.03 | 2.35 | 4.50 |
| 2025-12-31 | BIIB | -1.03 | 2.35 | 4.50 |
| 2026-01-02 | BIIB | -1.03 | 2.35 | 4.50 |
| 2026-01-05 | BIIB | -1.03 | 2.35 | 4.50 |
| 2026-01-06 | BIIB | -1.03 | 2.35 | 4.50 |
| 2026-01-07 | BIIB | -1.03 | 2.35 | 4.50 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
4.81
Avg. EPS Est. Current Quarter
1.75
Avg. EPS Est. Next Quarter
3.54
Insider Transactions
-1.03
Institutional Transactions
2.35
Beta
0.16
Average Sales Estimate Current Quarter
2214
Average Sales Estimate Next Quarter
2258
Fair Value
211.16
Quality Score
89
Growth Score
55
Sentiment Score
74
Actual DrawDown %
60.1
Max Drawdown 5-Year %
-72.7
Target Price
184.56
P/E
17.05
Forward P/E
12.33
PEG
P/S
2.83
P/B
1.51
P/Free Cash Flow
11.9
EPS
10.97
Average EPS Est. Cur. Y
15.03
EPS Next Y. (Est.)
15.22
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
16.6
Relative Volume
1.1
Return on Equity vs Sector %
-18.2
Return on Equity vs Industry %
-27.8
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.02
EBIT Estimation
316.2
Biogen Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 7605
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
stock quote shares BIIB – Biogen Inc. Stock Price stock today
news today BIIB – Biogen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BIIB – Biogen Inc. yahoo finance google finance
stock history BIIB – Biogen Inc. invest stock market
stock prices BIIB premarket after hours
ticker BIIB fair value insiders trading